Project Grant R21HL184238
Award Date 8/10/26
Completion Date 7/31/28
Dollars Obligated $232K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
East Lansing, MI 48824, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Michigan State University (Henry Ford Health+Michigan State University Health Sciences) $466,362 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to elucidate the mechanisms by which mitochondrial calcium overload impairs cellular energy metabolism. The project uses cryo-electron microscopy and computational physiology to investigate how calcium sequestration regulates oxidative metabolism across multiple...
- The National Heart, Lung, and Blood Institute awarded Lawrence Technological University $444,589 on July 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop multiscale computational modeling for assessing shear-induced bleeding risk in blood-contacting medical devices. The research addresses device-induced complications in blood-contacting medical devices used to manage and treat heart conditions. The project develops physics-based computational models to...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Michigan $724,200 on July 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate endothelial cell fate switches and dysfunction driven by fibrotic matrix remodeling. The research uses mouse models and an in vitro human microphysiological system of arteriole and venule-scale microvessels embedded within tunable stromal mimetic matrices to demonstrate how fibrotic physical cues...
- The National Heart, Lung, and Blood Institute (NHLBI) at the Department of Health and Human Services awarded The Leland Stanford Junior University $755,271 on August 25, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop, validate, and clinically evaluate a magnetic resonance imaging method for assessing blood flow hemodynamics in pediatric and young adult congenital heart disease patients. The project will augment 4D-flow MRI capabilities to enable direct...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $767,249 on June 22, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate computational models for designing organ-scale vasculature in biomanufactured cardiac tissues. The project addresses the need for patient-specific engineered tissues to repair complex congenital heart defects, particularly large ventricular septal defects where current surgical approaches...
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $174,621 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop cardiac magnetic resonance imaging (CMR) techniques for monitoring congenital heart disease using ultra-low field (ULF) MRI systems. The recipient will adapt CMR to an inexpensive, unshielded, open-geometry ULF MRI system and apply machine learning techniques to mitigate hardware limitations and...
- The National Heart, Lung, and Blood Institute awarded Regents of the University of Michigan $2,257,845 under a Project Grant (R01HL180433) on September 20, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds development of a real-time, non-invasive micro-rheology technique to characterize aging thrombi using ultrasound-responsive nanodroplets. The nanodroplets phase-transition into microbubbles when exposed to focused ultrasound above a threshold amplitude—a...
- The National Heart Lung and Blood Institute awarded the Regents of the University of Michigan $567,166 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop tunable multi-thrombolytic nanoformulations for treating ischemic stroke with minimal hemorrhagic risk. The research addresses limitations of current thrombolytic therapy—tissue plasminogen activator (tPA) carries serious intracranial hemorrhage complications, while plasmin, a more effective...
- The National Science Foundation Division of Civil, Mechanical, and Manufacturing Innovation awarded Michigan State University $370,721 on September 1, 2026, under the Engineering grant program (CFDA 47.041) to develop an integrated experimental and computational framework characterizing coronary blood vessel mechanics and their interaction with heart muscle tissue. The research establishes a multiscale model coupling coronary blood flow with cardiac mechanics, incorporating vascular impedance...
- The National Heart, Lung, and Blood Institute awarded Michigan State University (doing business as Henry Ford Health+Michigan State University Health Sciences) $1,099,000 on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop precision circadian medicine solutions for shift workers managing shift work disorder. The award funds research scaling digital health technologies, including consumer-based wearables, to track and manage circadian rhythms in nightshift...